Proteomics International Laboratories Ltd

Investor Presentation

September 2026

ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia

Disclaimer

This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ).

This Presentation may contain forward-looking statements, including quantitative statements of anticipated future financial performance such as projections, forecasts, calculations, forward-looking statements or estimates all of which are based on assumptions and estimates made by the Company as at the date of this document. Forward-looking statements can generally be identified by words such as “may”, “will”, “expect”, “intend”, “plan”, “estimate”, “forecast”, “anticipate”, “continue”, “guidance”, “target” and similar expressions. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company that may cause actual results, performance or achievements to differ materially from those expressed or implied in such statements.

Proteomics undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this document, except as required by applicable law or regulation. Forward-looking statements in this document speak only as at the date of this document. Readers should not place undue reliance on forward-looking statements. Each reader should undertake their own independent review of the forward-looking Statements, including the assumptions on which they are based and the financial calculations from which they are derived.

This presentation and/or any information obtained from the Company, its Directors or their associates, should not be relied upon in deciding whether or not to seek to purchase the shares of the Company. This is not an offer to subscribe for securities in the Company.

INVESTMENT OVERVIEW

Executive Summary

Proteomics International is commercialising three clinically validated prognostic and diagnostic tests that address unmet clinical needs. With Healius appointed as its exclusive Australian pathology distributor, the Company is focused on executing the Australian launch, with the United States as the larger medium-term opportunity.

Commercial pathway secured	• Exclusive three-year Australian pathology distribution agreement with Healius signed 22 July 2026, with a mutual three-year option, covering all three Promarker tests across approximately 1,900 patient collection centres • Controlled market roll-out in Western Australia and the Northern Territory announced on 14 September, ahead of national rollout expected in Q2 FY27 • Initial United States distributor appointment targeted for 2H FY27 • Distributor-led model replaces the discontinued direct-to-consumer approach
Platform and portfolio	• Accredited proteomics diagnostics business advancing three blood-based prognostic and diagnostic tests: Promarker D, Promarker Eso and Promarker Endo • Proteome-based testing detects dynamic biochemical change, supporting prognosis, diagnosis and risk assessment beyond what genomics alone provides • NATA, CLIA and CAP accredited laboratory operations in Australia and the United States
Clinically validated	• Promarker D: predicts diabetes-related chronic kidney disease up to four years before symptoms. 76 to 85% sensitivity, 92 to 95% specificity, NPV 95 to 97%, AUC 0.78 to 0.88. Multi-year validation complete • Promarker Eso: rules out oesophageal adenocarcinoma in chronic reflux patients. 91% sensitivity, 98% specificity, NPV 99.9%, AUC above 0.98 • Promarker Endo: early diagnosis of endometriosis. 83% sensitivity, 95% specificity, AUC above 0.92. Validation across independent cohorts underway; targeted for completion end December 2026, subject to receipt of the required sample cohort
Market opportunity	• Large addressable market with attractive competitive dynamics • Serviceable obtainable market across the three primary tests of approximately 85,000 annual tests in Australia and approximately 990,000 in the United States • Chronic, high-burden and frequently under-diagnosed indications with long diagnostic delays and invasive incumbent pathways
Reimbursement progressing	• United States: CPT PLA code 0579U granted for the next-generation Promarker D and CMS national reimbursement price of US$390.75 per test set under the Clinical Laboratory Fee Schedule, effective 1 January 2026. Medicare coverage is being sought through MolDX and a Local Coverage Determination, along side private payer coverage • Australia: commercialisation commences on a private pay basis while clinical and health economic evidence is accumulated. MSAC evaluation and MBS listing are medium-term objectives

CMS reimbursement price per ASX announcement 26 November 2025. PLA code 0579U per ASX announcement 3 July 2025. A CMS payment rate determines the amount payable for a covered claim and does not of itself establish Medicare coverage.

INVESTMENT HIGHLIGHTS

Why Proteomics

A multi-asset diagnostics portfolio at the point of commercial launch, with the distribution and reimbursement building blocks now in place.

1. **Three clinically validated tests, each addressing a long-standing diagnostic gap**
   Promarker Endo for endometriosis, where diagnosis is frequently delayed for years. Promarker Eso to rule out oesophageal cancer without surveillance endoscopy. Promarker D, the first proteomics-derived test able to predict diabetes-related kidney disease up to four years before symptoms

2. **Poised for growth with national Australian distribution secured**
   Three-year exclusive pathology distribution agreement with Healius, with a mutual three-year option, providing access to approximately 1,900 patient collection centres across all three Promarker tests

3. **Large addressable markets, with pricing established for two of three tests**
   Australian patient pricing established at A$495 for Promarker D and A$997 for Promarker Eso, implying approximately A$25m per annum at serviceable obtainable volumes of 35,000 tests. Promarker Endo pricing is not yet set and would add a further 50,000 annual tests once confirmed. United States serviceable obtainable market of approximately 990,000 annual tests

4. **Catalyst-rich near term**
   Phased Australian market release through Healius from September 2026, Promarker Endo validation completion, an initial United States distributor appointment targeted for 2H FY27, and reimbursement submissions progressing in both markets

5. **Accredited laboratory infrastructure and protected position**
   NATA, CLIA and CAP accredited operations provide regulated capacity in both target markets. Granted patent families across the portfolio include a United States Promarker Endo patent running to March 2041

6. **Reconstituted board and management with commercialisation mandate**
   New Chief Executive Officer appointed in 2026 following the founder's retirement, alongside a board with life sciences, global pharmaceutical and listed company operating experience

STRATEGIC ROADMAP

Execution Plan – The Next 3 Years

The strategic roadmap outlines the 3 year plan focused on commercialisation, fostering innovation, scaling processes and infrastructure, and enhancing our capabilities to achieve sustainable long term value.

RESET
2H FY26

- ✓ Discontinued the DTC business model
- ✓ Engaged with potential distribution partners in Australia and the USA
- ✓ Continued Promarker Endo assay validation
- ✓ Continued refinement of Promarker Eso assay and streamlined lab protocols
- ✓ Restructured the leadership team and organisation
- ✓ Commenced the OxiDx strategic review
- ✓ Reviewed IP portfolio

ACCESS
1H FY27

- ✓ Advance laboratory processes, quality systems and information systems in Australia
- ✓ Appointed distributor partner in Australia
- ✓ Commence phased, controlled market releases in Australia
- Develop reimbursement strategy for Australia and the USA
- Finalise assay validations and clinical protocols for Promarker Endo

ADVANCE
2H FY27

- Appoint distributor partners in the USA
- Establish Proteomics team in the USA
- Optimise test turnaround times, reporting, and customer experience
- Prepare reimbursement dossiers and commence submissions for Australia and USA
- Maintain and build investor confidence through achievement of milestones

ACCELERATE
FY28

- Broaden distributor network coverage
- Increase awareness and test utilisation across clinical indications
- Expand laboratory capacity and support functions in line with demand
- Manage reimbursement submissions and engagement processes
- Publish clinical utility and health economic evidence to support adoption and reimbursement

ACHIEVE
FY29

- Enhance distributor performance management
- Expand product portfolio pipeline
- Streamline laboratory and commercial operations
- Improve operating leverage
- Develop strategic growth options to drive product and geographic expansion

SECTION TWO

Business and Portfolio

Platform, products, addressable market, route to market and reimbursement

COMPANY OVERVIEW

About Us

Proteomics International integrates extensive proteomics knowledge with accredited laboratory operations to bring validated diagnostic solutions to market, improving patient outcomes through earlier and more precise diagnoses.

Patient Outcomes

Committed to enhancing patient outcomes through earlier detection and more precise diagnoses of chronic, high burden, and often under diagnosed diseases.

Advanced Diagnostics

Specialising in diagnostic tests based on proteomics; the analysis of proteins that drive disease activity enabling richer clinical insight than genomics alone.

Test Solutions

Focused on clinically validated, minimally invasive blood based prognostic and diagnostic solutions that integrate seamlessly into routine clinical practice.

Complete Workflow

Extensive expertise covering biomarker identification, clinical validation, and compliant laboratory processes, encompassing everything from research to diagnostic implementation.

Our Operations

Headquartered in Perth, Western Australia, with NATA and CLIA/CAP certified laboratories in Australia and the United States providing regulated testing capacity across key markets.

Note:

1. NATA (National Association of Testing Authorities) Australia's accreditation authority. CLIA (Clinical Laboratory Improvement Amendments), USA regulatory baseline for lab testing. CAP (College of American Pathologists) USA accreditation program that exceeds CLIA standards.

PORTFOLIO

Innovation Portfolio – Four Tests

Proteomics International provides a suite of four prognostic and diagnostic tests targeting specific clinical areas of unmet need. Our priority is to validate and commercialise these tests before developing new tests for other medical conditions.

Promarker D

- Prognostic blood test to predict the risk of diabetes related chronic kidney disease up to 4 years before symptoms appear, enabling earlier clinical intervention and ongoing monitoring.

Promarker Eso

- Diagnostic blood test for patients with chronic reflux that detects specific protein changes to rule out oesophageal adenocarcinoma, thus reducing the need for invasive surveillance endoscopy procedures.

Promarker Endo

- Diagnostic blood test for patients with symptoms suggestive of endometriosis, thus reducing the extensive delays in diagnosis and management.

OxiDx

- Proprietary platform for measuring oxidative stress, focusing on diagnostic or specialised applications where there is clear clinical value and economic benefits.

PORTFOLIO

Innovation Portfolio – Market Potential

We have assessed the market opportunities for our three primary tests in both Australia and the United States. Our analysis indicates that the serviceable obtainable market opportunity is substantial, offering significant growth potential.

Market Potential Australia – Annual Test Volumes (‘000)



Market Potential USA – Annual Test Volumes (‘000)



Definitions: Total Addressable Market (TAM) assumes unconstrained access and reimbursement. Serviceable Available Market (SAM) considerschallenges associated with pathway, workflow, and reimbursement. Serviceable Obtainable Market (SOM) reflects realistic medium-term commercial penetration opportunities.

1. **Promarker D assumptions:** T2D patients in active care, pre-advanced CKD. Tested once every 4 years. 65% of diagnosed T2D addressable. SAM 60% of TAM; SOM 15% of SAM.
2. **Promarker Eso assumptions:** Chronic reflux patients with appropriate risk factors. Tested once every 3 years. 15% of managed reflux patients. SAM 70% of TAM; SOM 25% of SAM.
3. **Promarker Endo assumptions:** Reproductive-age women (15–49) with suspected endometriosis. Tested once per clinical work-up. 10% prevalence; 55% undiagnosed; 35% enter active work-up annually. SAM 80% of TAM; SOM 30% of SAM.

Sources: Population data from ABS and U.S. Census Bureau 2025 estimates. Promarker D: AIHW/NDSS (AU); U.S. Census Bureau/CDC (US). Promarker Eso: AIHW/RACGP (AU); NIDDK/U.S. reflux studies (US). Promarker Endo: ABS/AIHW (AU); U.S. Census Bureau/women’s health literature (US).

PRODUCT OVERVIEW

Promarker D – Chronic Kidney Disease

Prognostic blood test to predict the risk of diabetes related chronic kidney disease up to 4 years before symptoms appear, enabling earlier clinical intervention and ongoing monitoring.

Clinical Value

Identifies high risk patients with diabetes before irreversible kidney damage occurs.

Clinical Performance

76–85% sensitivity, 92–95% specificity, NPV 95-97%, AUC 0.78–0.88. Multi year validation completed.

Intellectual Property

Global patent portfolio covering biomarkers, and clinical applications.

Market Opportunity

SOM reflects realistic medium term annual commercial opportunities. ~20,000 patients in Australia and ~390,000 in the USA.

Clinical Pathway

Blood sample taken during regular diabetes check ups guides monitoring by GPs and nephrologists and is done every 4 years.

Reimbursement

Initial private pay in Australia and the USA, with plans for insurance and public funding; CMS PLA code granted; CMS price US$390.75 per test from 1 January 2026, MolDX coverage pending.

Key Actions

- **Appoint distributor partner** in the USA
- Collaborate with distributors on market entry and **product launches**
- Leverage clinical advisory board to **increase awareness**
- Commence **reimbursement applications**
- Increase **lab capacity** to meet demand and improve turnaround times

Notes:

1. Sensitivity (True Positive Rate), The proportion of actual positives correctly identified. Specificity (True Negative Rate) The proportion of actual negatives correctly identified. NPV (Negative Predictive Value) The probability that someone with a negative test truly does not have the condition. AUC (Area Under the ROC Curve) A summary measure of a model's ability to distinguish between classes (disease versus no disease).
2. CMS (Centers for Medicare & Medicaid Services). PLA (Proprietary Laboratory Analysis) A code recognised by CMS that uniquely identifies a specific proprietary clinical laboratory test for Medicare pricing and billing purposes.

PRODUCT OVERVIEW

Promarker Eso – Oesophageal Cancer

Minimally invasive diagnostic blood test for patients with chronic reflux that detects specific protein changes to rule out oesophageal adenocarcinoma, thus reducing the need for invasive surveillance endoscopy procedures.

Clinical Value

Identifies patients with chronic reflux at risk of oesophageal cancer, reducing the need for invasive surveillance endoscopic procedures.

Clinical Performance

91% sensitivity, 98% specificity, NPV 99.9%, AUC exceeding 0.98. Assay being validated across multiple cohorts.

Intellectual Property

Globally granted patent family protecting key biomarkers and clinical applications.

Market Opportunity

SOM reflects realistic medium term annual commercial opportunities. ~15,000 patients in Australia and ~240,000 in the USA.

Clinical Pathway

Blood sample taken during regular check ups guides monitoring by GPs and gastroenterologists and is done every 3 years.

Reimbursement

Initial private pay in Australia and the USA, with plans for insurance and public funding.

Key Actions

- **Refine assay** and streamline lab protocols
- **Appoint distributor partner** in the USA
- Collaborate with distributors on market entry and **product launches**
- Leverage clinical advisory board to **increase awareness**
- Commence **reimbursement applications**
- Increase **lab capacity** to meet demand and improve turnaround times

Note:

1. Sensitivity (True Positive Rate), The proportion of actual positives correctly identified. Specificity (True Negative Rate) The proportion of actual negatives correctly identified. NPV (Negative Predictive Value) The probability that someone with a negative test truly does not have the condition. AUC (Area Under the ROC Curve) A summary measure of a model's ability to distinguish between classes (disease versus no disease).

PRODUCT OVERVIEW

Promarker Endo – Endometriosis

Diagnostic blood test for patients with symptoms suggestive of endometriosis, thus reducing the extensive delays in diagnosis and management.

Clinical Value

Identifies patients with a high risk of endometriosis, shortening the typical 7-10 year delay in diagnosis.

Clinical Performance

83% sensitivity, 95% specificity, NPV 75%, AUC exceeding 0.92. Assay being validated across independent cohorts.

Intellectual Property

Broad international patent portfolio with initial patents secured.

Market Opportunity

SOM reflects realistic medium term annual commercial opportunities. ~50,000 patients in Australia and ~360,000 in the USA.

Clinical Pathway

Blood sample is taken to help GPs and gynaecologists evaluate patients who may have endometriosis.

Reimbursement

Initial private pay in Australia and the USA, with plans for insurance and public funding.

Key Actions

- **Complete assay validation** across independent cohorts.
- **Appoint distributor partner** in the USA
- Collaborate with distributors on market entry and **product launches**
- Establish clinical advisory boards to **increase awareness**
- Commence **reimbursement applications**
- Increase **lab capacity** to meet demand and improve turnaround times

Note:

1. Sensitivity (True Positive Rate), The proportion of actual positives correctly identified. Specificity (True Negative Rate) The proportion of actual negatives correctly identified. NPV (Negative Predictive Value) The probability that someone with a negative test truly does not have the condition. AUC (Area Under the ROC Curve) A summary measure of a model's ability to distinguish between classes (disease versus no disease).

Disciplined Path to Commercial Success

Proteomics International has shifted its emphasis to disciplined commercial execution, advancing a range of prognostic and diagnostic tests through clearly defined development phases, while maintaining strict control over capital management.

Leveraging Proteomics Expertise

Leveraging our proteomics expertise, accredited laboratories and capabilities to deliver clinically validated and regulatory compliant tests.

Executing Disciplined Commercial Launches

Executing disciplined commercial launches to ensure all product launches are aligned with validated clinical tests, operational readiness, and market awareness and development.

Converting Research into Clinical Solutions

Converting years of research into a disciplined, clinically validated portfolio with clear pathways to adoption and measurable clinical and commercial outcomes.

Securing Reimbursement

Progressing reimbursement in Australia and the USA through a structured pathway that combines early private pay with ongoing evidence generation to support sustainable reimbursed market access.

Implementing Distributor Business Models

Implementing distributor partner business models to deliver faster adoption, lower execution risk, and superior capital efficiency compared to any direct or hybrid alternative.

Allocating Capital with Discipline

Prioritising investments that deliver commercial growth, validated product performance, support reimbursement, build capabilities, improve operational efficiency, and maintain capital discipline.

DISTRIBUTION MODEL

Distribution Partnerships to Accelerate Adoption

The distributor model delivers faster adoption, lower execution risk, and superior capital efficiency compared to any direct or hybrid alternative.

Characteristics of the Distribution Model

Distributor Access

Distributor provides clinician access via their established networks

Seamless Integration

Ordering, sample collection, and logistics are incorporated into existing distributor workflows

Regulated Testing

Testing is conducted in Proteomics' laboratories following regulatory guidelines

Quality Assurance

Proteomics oversees quality control, regulatory compliance, and reporting

Key Success Factors

- **Builds upon experiences** from earlier direct and hybrid models
- Leverages trusted **diagnostic and provider networks**
- **Avoids costs, complications, and risks** associated with proprietary infrastructure
- **Integrates seamlessly** into current clinical workflows
- Reduces **operational and compliance risks** through proven and validated platforms
- Establishes a **scalable and repeatable commercial model** to support long term growth

ROUTE TO MARKET

Exclusive Australian Distribution Agreement

The agreement provides national pathology distribution for the full Promarker portfolio and removes the need to build a proprietary collection and referrer network in Australia.

Key terms	
Counterparty	Healius Limited (ASX:HLS), one of Australia's largest pathology networks
Scope	Exclusive Australian pathology distribution of Promarker D, Promarker Eso and Promarker Endo
Term	Initial three years, with an option to extend for a further three years by mutual agreement
Reach	Approximately 1,900 patient collection centres, and established general practitioner, specialist, hospital and healthcare provider relationships
Healius responsibilities	Specimen collection, pathology distribution, referrer engagement and market access
Company responsibilities	Testing, clinical reporting and scientific support and quality and regulatory compliance, with all testing conducted in the Company's accredited laboratories
Joint workstreams	Operational and IT integration, laboratory workflow implementation, clinician education and engagement, market access planning and launch preparation
Rollout	Phased commercial rollout expected during FY27. Controlled market release in Western Australia and the Northern Territory announced on 14 September 2026, ahead of national rollout expected to follow in Q2 FY27
Pricing	Australian patient pricing (private pay), per ASX announcement 14 September 2026: • Promarker D – A$495 • Promarker Eso – A$997
Commercial terms	**Confidential. Revenue under the agreement cannot be reliably estimated at this time**

What the agreement changes

- Immediate national reach without the cost, complexity and execution risk of proprietary collection infrastructure
- Places the tests inside an existing clinical ordering workflow that referrers already use
- Validates the distributor-led model adopted after the direct-to-consumer approach was discontinued
- Delivers the FY27 H1 objective of appointing an Australian distributor ahead of schedule
- Creates a template for the United States distributor appointment targeted in 2H FY27

Source: ASX announcement, 22 July 2026 and 14 September 2026. Terms as disclosed. Rollout timing is indicative and subject to change

MARKET OPPORTUNITY

Serviceable Market and Pricing per Test

Australian patient pricing is set for Promarker D and Promarker Eso, an indicative A$25 million per annum at serviceable obtainable volumes. Promarker Endo pricing follows completion of validation and would add 50,000 annual tests to that base.

AUSTRALIA | Private pay pricing set for Promarker D and Promarker Eso, MBS listing a medium-term objective

Test	Indication	SOM, annual tests	Patient price	Indicative value	Status
Promarker D	Chronic kidney disease in type 2 diabetes	20,000	A$495	A$9.9m pa	Launch ready
Promarker Eso	Oesophageal cancer rule-out in chronic reflux	15,000	A$997	A$15.0m pa	Launch ready
Subtotal, Promarker D and Eso		**35,000**		**A$24.9m pa**	
Promarker Endo	Endometriosis	50,000	TBA	TBA	Validation to complete

UNITED STATES | Medicare payment rate set for Promarker D, coverage still being sought

Test	Billing	SOM, annual tests	Reference price	Indicative value	Status
Promarker D	CPT PLA code 0579U	390,000	US$390.75	**US$152m pa**	CMS payment rate, coverage pending
Promarker Eso	No code assigned	240,000	TBA	TBA	Pricing to be established
Promarker Endo	No code assigned	360,000	TBA	TBA	Pricing to be established
Total, three tests		**990,000**			

Source: Australian patient pricing per ASX announcement 14 September 2026. United States reimbursement price per ASX announcement 26 November 2025 (CPT PLA code 0579U, next-generation Promarker D, effective 1 January 2026). Serviceable obtainable market per the Company's market analysis, reflecting realistic medium-term commercial penetration. Indicative values are illustrative only.

Reimbursement Pathways – Australia

Australia provides a national reimbursement framework for prognostic and diagnostic tests. Achieving Medicare Benefits Schedule (MBS) listing is a medium term objective that will serve as a significant driver of growth.

Reimbursement Process

Private Pay

Commercialisation begins outside Medicare, generating early revenue and real world Australian evidence

Evidence Accumulation

Clinical and health economic information is collected to demonstrate the impact on decisions and patient outcomes

MSAC Evaluation

The Medical Services Advisory Committee (MSAC) independently evaluates the test and assigns a relevant MBS item number

MBS Listing

Approval grants a nationwide MBS listing, expanding accessibility and promoting increased volume

Key Considerations

- A national reimbursement framework for tests is established
- Company tests are gathering clinical and health economic evidence
- MBS listing is a key medium term growth objective
- MSAC may approve, delay, or reject pending more evidence
- Timelines are long, but understood
- MBS listing secures long term patient access

Reimbursement Pathways – USA

In the United States, reimbursement for prognostic and diagnostic tests is decentralised and based on evidence, growing incrementally through private and public funding.

Reimbursement Process

Private Pay

Commercialisation begins with private pay options, hospital networks, and employer sponsored programs

Evidence Accumulation

Clinical and health economic information is collected during clinical use alongside individual payer coverage decisions

MolDX Evaluation

Medicare reimbursement depends on MolDX approval, which requires a detailed review of analytical validity, clinical utility, and medical necessity

Expanded Coverage

Coverage progressively extends across different regions and payer groups through CMS/MAC for Local Coverage Determination (LCD)

Key Considerations

- The USA has no unified reimbursement system; coverage is split between Medicare, Medicaid and various private payers
- Ongoing engagement with multiple payers is essential
- Early progress often comes from private payers and hospital networks
- Reimbursement and coverage timelines differ and expand over time
- Unlike Australia's MBS, the USA requires multiple negotiations with many payers

Note:

1. MolDX (Molecular Diagnostic Services Program) A CMS program that evaluates molecular tests to determine if they are reliable, clinically useful, and medically necessary for Medicare coverage. CMS (Centers for Medicare & Medicaid Services) The U.S. federal agency that oversees Medicare and sets national coverage policies. MAC (Medicare Administrative Contractor) Regional contractors that process claims and make local coverage decisions for Medicare. LCD (Local Coverage Determination) A region-specific policy that defines when a service or test is covered by Medicare.

LEADERSHIP

Board of Directors

Dr James Williams Non-Executive Chair
PhD, MBA, BSc (Hons) GAICD

Seasoned life sciences executive with experience from startup to commercialisation.

Former CEO/CTO/Chair across multiple biotech companies (incl. Dimerix, iCeutica).

Contributed to development of five FDA-approved drugs, devices, and diagnostics.

David Morris CEO & Managing Director
BBus, BAppSc, GAICD

Global healthcare and medtech executive.

Proven track record in commercial growth, product commercialisation, and international expansion.

Deep experience in strategy, regulatory pathways, and global market development across US, Europe, and Asia.

Aaron Brinkworth Non-Executive Director
BHIthSc, GAICD

Global pharmaceutical executive with 22+ years at Gilead Sciences (Nasdaq: GILD).

Led Asia Pacific commercial, market access, and strategic licensing functions.

Deep experience in scaling sales, marketing, and distribution across complex regions.

Paul House Non-Executive Director
BEng (Hons), GAICD

Senior executive with 25+ years across multinational corporations and consulting.

CEO of Imdex (ASX: IMD); former MD of SGS India and CFO/COO in global roles.

Strong track record in operational leadership, finance, and international growth.

Vicki Robinson Non-Executive Director
LLB (Hons), BCom, MAICD

Experienced non-executive and former Wesfarmers senior executive with 20+ years in legal and commercial leadership.

Served on Wesfarmers Leadership Team and as Company Secretary across group entities.

Deep experience in strategy, M&A, governance, risk, and regulatory environments.

Appendix

PLATFORM

Science of Proteomics

The proteome offers a more complete view of disease than genomics. Turning biochemistry into validated prognostics and diagnostics requires precision, standardisation, and deep technical expertise.

Complexity Requires Expertise



- Protein levels can shift with disease stage, treatment, and patient factors.
- Results depend heavily on sample handling and storage conditions.
- Requires rigorous clinical, analytical, and regulatory validation.

What is Proteomics

- Analyses proteins that drive biological processes including disease progression.
- Identifies dynamic biochemical changes, including treatment response.
- Supports prognosis, diagnosis, risk assessment, and clinical decision making.

PATIENT JOURNEY

Patient Care Ecosystem

The patient journey involves clear roles for patients, clinicians, distributors, and labs. Proteomics International handles development and testing, while partners manage market access, ensuring accountability and quality from collection to result.

	IDENTIFY	COLLECT	ANALYSE	INFORM	ACT
Patient	Presents and consents	Provide blood sample		Receives results via clinician	Receives personalised care advice
Clinician	Assesses and orders test			Interprets test result	Manages treatment or referral
Distributor	Enables access and ordering	Collects blood and manages logistics	Tracks samples and turnaround	Supports report delivery	Supports repeat testing
Proteomics	***Defines indications***	***Sets collection standards***	***Performs testing and quality control***	***Issues decision ready report***	***Captures outcomes***

ENTERPRISE PRIORITIES

Strategic Framework for Execution

Enterprise objectives create a clear framework aligning strategy with execution, focusing on areas of commercial execution, innovation, operations, and organisational capabilities to deliver lasting value for patients, partners, and investors.

DRIVE COMMERCIAL EXECUTION

- Transform clinically validated diagnostics into a scalable business model
- Establish distributor led market access in Australia and the USA
- Promote adoption via phased market launches
- Integrate tests into routine clinical practice
- Secure reimbursement and payer coverage with robust evidence

INNOVATE PORTFOLIO

- Develop products with strong commercial and reimbursement potential
- Conduct biomarker research based on clear clinical needs
- Maintain strict scientific and clinical standards
- Produce dependable clinical and economic evidence
- Ensure robust intellectual property portfolio

OPTIMISE OPERATIONS

- Deliver dependable test access with scalable, consistent service
- Implement standardised systems and workflows
- Expand laboratory operations in response to demand
- Increase efficiency in turnaround times and throughput
- Strengthen quality control and regulatory compliance

BUILD ORGANISATION CAPABILITIES

- Establish a clear structure, roles and responsibilities
- Strengthen leadership capabilities
- Attract and retain key technical and commercial talent
- Embed disciplined performance management
- Foster a culture centered on commercialisation, execution, quality, and compliance

DELIVER SUSTAINABLE VALUE

- Prioritise growing revenue and sustainable profit margins
- Maintain capital efficiency alongside rigorous cost control
- Adopt a proactive approach to risk management
- Develop strategic growth options through partnerships to drive expansion
- Increase long term shareholder value

PRODUCT OVERVIEW

OxiDx – Oxidative Stress Platform

Proprietary platform for measuring oxidative stress, focusing on diagnostic or specialised applications where there is clear clinical value and economic benefits.

Clinical Value

Provides an objective measurement of oxidative stress in specialised environments where standardised tests are unavailable.

Market Opportunity

SOM reflects realistic medium term annual commercial opportunities. ~60,000 tests in Australia and ~1,200,000 test in the USA.

Clinical Performance

Established platform technology with performance assessed on a per indication basis.

Clinical Pathway

Blood sample is taken to help doctors or specialists evaluate patient's oxidative stress levels and manage changes over time.

Intellectual Property

Patents granted across key markets.

Reimbursement

Initial private pay in Australia and the USA.

Key Actions

- Continue to collect **clinical and real world evidence**
- Develop elite athlete and equine **business models** and confirm priority segments
- **Confirm capital investment** required to progress from research stage to a commercial business
- **Determine strategic options** and best approach to commercialisation

Sources: Population data from ABS and U.S. Census Bureau 2025 estimates. Australian Government (Dept. of Health and Aged Care); Australian Institute of Sport (AIS); Australian Sports Commission (AusPlay); National Collegiate Athletic Association (NCAA); United States Olympic & Paralympic Committee (USOPC)

Note:

1. OxiDx assumptions: 25,000 elite athletes in Australia. 500,000 elite athletes in the USA. Assume 12 tests per year. SAM 65% of TAM; SOM 30% of SAM. Does not include Equine market potential.

Proteomics International
Laboratories Ltd

ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia